- Home
- AVTX vs ASMB Comparison
AVTX vs ASMB Comparison
Compare AVTX & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVTX | ASMB |
|---|---|---|
| Founded | 2011 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 888.6M | 512.1M |
| IPO Year | 2015 | 2010 |
Fundamental Metrics
Financial Performance| Metric | AVTX | ASMB |
|---|---|---|
| Price | $15.58 | $23.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $40.57 | ★ $44.20 |
| AVG Volume (30 Days) | ★ 908.0K | 315.9K |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 72.07 | ★ 91.78 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,813,137.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $638.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 2312.27 | N/A |
| 52 Week Low | $12.41 | $21.80 |
| 52 Week High | $24.27 | $39.71 |
Technical Indicators
Market Signals| Indicator | AVTX | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 35.31 | 28.54 |
| Support Level | $15.29 | $21.80 |
| Resistance Level | $20.54 | $30.62 |
| Average True Range (ATR) | 1.08 | 1.71 |
| MACD | -0.18 | -0.88 |
| Stochastic Oscillator | 16.07 | 3.77 |
Price Performance
Historical ComparisonAbout AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.